Sudden unexpected death in epilepsy: is carbamazepine implicated?  by Timmings, P.L.
Seizure 1998; 7: 289-291 
Sudden unexpected death in epilepsy: is 
carbamazepine implicated? 
I? L. TIMMINGS 
Waikato Hospital, PO Box 3200, Hamilton, New Zealand 
Sudden unexpected death in epilepsy (SUDEP) has been recognised for centuries. The precise frequency of occurrence is not 
well defined. Education of medical professionals is needed, so that death certificates and coronial inquests may appropriately, 
correctly and consistently record SUDEP as the case of death. Correct identification will then allow further investigation of this 
misunderstood, and often ignored. epilepsy complication. SUDEP incidence may be increasing, either-as a result of increased 
recognition, or possibly due to a real increase in incidence. All currently available antiepileptic drugs (AEDs) have been associated 
with SUDEP, and current opinion assumes that the relative proportion of patients suffering SUDEP is representative of average 
AED usage type for a particular time and locality, however, recently analysed data suggest a strong bias towards carbamazepine. A 
review of Cardiff Epilepsy Unit data shows that carbamazepine was disproportionately represented in patients suffering SUDEP. 
In this series, I 1 of the 14 SUDEP patients were taking carbamazepine at the time of death. This was calculated as 79% of all 
patients, compared to average carbamazepine usage by all other Cardiff Epilepsy Unit patients of 38%. The data also indicate 
that one patient was not taking any drug therapy, and died during his first seizure, reducing the number of evaluable ‘drug usage’ 
patients to 13, and increasing the proportion taking carbamazepine at the time of death to 85%. (P -Z 0.01). Possible mechanisms 
include carbamazepine induced lengthening of the ECG Q-T interval combined with a mild pro-at-rhythmic effect of epileptic 
seizure discharges, and consequent transient cardiac instability leading to arrhythmic death. Or alternatively, excessive post- 
seizure brainstem inhibition might result in blunting or transient abolition of central hypoxic and hypercarbic respiratory drive, 
with consequent post-ictal respiratory arrest. subsequent exacerbation of hypoxia, further cardiac destabilisation and death due to 
hypoxia/failed re-establishment of respiration and terminal cardiac arrhythmia. Current knowledge about SUDEP remains poor. 
Education is needed so that case ascertainment can be correctly documented. Delineation of the precise mechanisms involved 
should lead to definitive prevention strategies. Evaluation of carbamazepine as a significant causative factor in SUDEP is also 
needed. 
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INTRODUCTION 
Patients with epilepsy have a mortality rate which is 
significantly greater than the general population’. The 
excess is composed of an increased incidence of in- 
tracranial neoplasm, increased incidence of seizure re- 
lated death, i.e. accidents, asphyxia/aspiration and sta- 
tus epilepticus, and an increased incidence of sudden 
unexpected death. 
Sudden unexpected death in epilepsy (SUDEP) 
has been recognised for centuries, and pre-dates the 
widespread use of modem antiepileptic drugs (ABDs). 
It, as the name implies, is the occurrence of unexpected 
(and unexplained) death in a patient with epilepsy. 
There is considerable confusion about what constitutes 
a SUDEP, and inaccurate death certificate classification 
has resulted in significant under-reporting*. SUDEP is 
a separate entity from asphyxia, aspiration and status 
epilepticus. Because of reporting and classification dif- 
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ficulties the precise frequency is difficult to quantify3, 
but appears to be increasing”. Some SUDEPs may be 
avoidable if causative factors can be correctly identified 
and avoided, mitigated or eliminated. 
Education of medical professionals who necessarily 
document these unfortunate deaths is urgently needed, 
so that death certificates and coronial inquests may ap- 
propriately, correctly and consistently record SUDEP 
as the cause of death. Consequently, when correct case 
ascertainment data are available further prospective 
studies of SUDEP mechanisms will become feasible. 
Recently reported SUDEP series deal with rather 
small numbers of patients and, consequently, small er- 
rors in numerator data can lead to significant errors in 
incidence estimate calculations. However, perhaps sur- 
prisingly, all the independent series compute a SUDEP 
risk of 1:370 to 1:1110 patient treatment years3v5T6. 
Of much more concern is an apparent association of 
SUDEP with carbamazepine. 
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All currently available AEDs have been associated 
with SUDEP, and initial impressions have been that the 
relative proportion of patients suffering SUDEP is rep- 
resentative and proportionate to average AED usage for 
a particular time and region. However, our series sug- 
gests that this assumption is not necessarily correct, 
and shows a strong bias towards carbamazepine as an 
associated factor. 
PATIENTS AND METHODS 
A prospective record of epilepsy patient deaths was 
maintained by the Cardiff Epilepsy Unit between 1984 
and 1992. For each case the register logged the cause 
of death, and also recorded associated factors: seizure 
types(s), AED therapy, demographic data and social 
circumstances of each deceased patient. The number 
of SUDEPs was extracted from the death register by 
subtracting deaths due to seizure-related events (i.e. 
accidents) and non-seizure-related deaths due to other 
medical conditions or events (e.g. tumours, cardiac dis- 
ease, non-seizure-related accidents, suicide, etc.). 
This method identified 14 episodes of SUDEP. Year- 
by-year analysis of the total number of patients regis- 
tered with the Unit allowed calculation of total patient- 
years and equated to 7000 patient-treatment-years, and 
produced a calculated SUDEP rate of 1 SUDEP per 
500 patients per year. 
RESULTS 
Analysis of the data collected produced results which 
parallelled the base population in many respects, and 
these are summarised in tables l-6. 
Table 1: Male-to-female ratio. 
SUDEP patients I .8: 1 (total 14 patients) (P < 0.05) 
Non-SUDEP patients 0.87: I (total 1851 patients) 
Table 2: Duration of epilepsy (at time of SJDEP), mean 19 yr. 
Duration (yr) No. of patients 
<I 1 
l-2 2 
3-5 0 
6-10 3 
> 10 8 
Table 3: Seizure types. 
Seizure type No. of patients 
Partial seizures only I 
Generalized tonic clonic seizures 13(P < 0.05) 
Table 4: Seizure freouencv. _ 
Monthly seizure frequency No. of patients 
<I 4 
I-4 5 
5-60 4 
Unknown I 
Table 5: Number of antiepileptic drugs per patient at time of 
death. 
No. of drugs taken No. of patients 
0 I 
I 7 
2 5 
3 I 
Table 6: Type of antiepileptic drug treatment. 
Number (%) of Number (8) of 
SUDEP non-SUDEP 
patients taking drug patients taking drug 
“w at time of death at time of death 
Carbamazepine I I (85%)” 712 (386) 
Viilproate 5 (36%) 552 (30%) 
Phenytoin 1(7%) 291 (16%) 
Phenobarbitone 
or primidone 2(14%) 126 (7%) 
Lamotrigine I (7%) 153 (8%) 
Nil I 17%) 
a Garbamazepine was particularly strongly associated with 
SUDEP Eleven of the I4 SUDEP patients were taking carb- 
amazepine at the time of death. One of the SUDEP patients 
was not taking any drug therapy. and died during his first 
seizure. reducing the number of evaluable ‘drug usage’ 
patients to 13; and increasing the proportion taking carb- 
amazepine at the time of death to 85%. (p c 0.01). 
Age at death ranged from 20-69 years and most pa- 
tients were aged 20-40 years, (mean: 35 years). Eleven 
of the 14 SUDEP patients were single, widowed or sep- 
arated, and lived or slept alone. 
Two strong statistically significant differences 
emerged: 
(1) a strong association of SUDEP with carbamazepine 
usage; 
(2) an association of SUDEP with living/sleeping 
alone. 
DISCUSSION 
The overall rate of SUDEP in this patient group of one 
death per 500 patient-years was similar to other reports, 
which range from l/l 110 to 1/37O3,6.7. This is the first 
series to suggest a specific bias towards carbamazepine 
(P c 0.01) as a risk factor. Previous retrospective anal- 
yses have tended to reflect average AED use for the 
respective time and location. 
The mechanism of the possible adverse carba- 
mazepine effect is unclear, and requires further eval- 
uation. It may relate to carbamazepine-induced length- 
ening of the ECG Q-T interval combined with a mild 
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pro-arrhythmic effect of epileptic seizure discharges, 
with consequent transient cardiac instability leading to 
arrhythmic death (tachy-arrhythmias and episodes of 
sinus arrest have been documented)3.8-‘6. This mecha- 
nism may also be relevant in cases of SUDEP occurring 
in patients taking oxcarbazepine. 
Another potential mechanism that merits further in- 
vestigation is the concept of excessive ‘brainstem in- 
hibition’, due to seizure-induced release of GABA 
and other neuro-inhibitory peptides. This is a normal 
(physiological) endogenous seizure-terminating mech- 
anism. However, excess brainstem inhibition could re- 
sult in blunting or transient abolition of central hy- 
poxic and hypercarbic respiratory drive, resulting in 
post-ictal respiratory arrest, subsequent exacerbation 
of hypoxia, further cardiac de-stabilisation and death 
due to hypoxia and secondary cardiac arrhythmia. This 
mechanism appears to have a degree of plausibility, as 
recent observational SUDEP data suggest that death 
might occur after, rather than during, a seizure, as a 
consequence of failed re-establishment of respiration 
in the post-ictal phase. 
CONCLUSION 
Current knowledge about SUDEP remains poor. Fur- 
ther education is needed so that case ascertainment 
can be correctly documented. Research into the precise 
mechanisms involved should lead to definitive preven- 
tion strategies. Further study to evaluate the role of 
carbamazepine as a causative factor in SUDEP is also 
needed, but in the interim caution with carbamazepine 
use seems prudent. 
REFERENCES 
I. Hauser, W.A. and Hesdorffer. D.C. Mortality. Epilepsy: Fre- 
qtrcrrc!: Causes a~ld Conser/uences. Maryland, Epilepsy Foun- 
dation of America, 1990: pp. 297-326. 
2. Brown. S.W., Mawer, GE., Lawler, E. er (I/. Sudden death and 
epilepsy. Lrrncef 1990; 335: 606-607. 
3. Leestma. J.E., Walczak, T., Hughes, J.R., Kalelkar, M.B. and 
Teas, S.S. A prospective study on sudden unexpected death in 
epilepsy. Annals ofNeurology 1989; 26: 295-203. 
4. Bet&, T. Frequency of SUDEP. Personal communication, 
Queen Elizabeth Psychiatric Hospital, Birmingham, UK, 1997. 
5. Klenerman. P, Sander, J.W.A.S. and Shorvon, S.D. Mortality in 
patients with epilepsy: a study of patients in long term residen- 
tial care. Journal ofNeurological and Nerrrosurgicol Psychiar~~ 
1993: 56: 149-152. 
6. Lip, G.Y.H. and Brodie, M.J. Sudden death in epilepsy: an 
avoidable outcome? Joumol of the Royal Sociery of Medicine 
1992; 85: 609-6 I I. 
7. Timmings, P.L. Sudden unexpected death in epilepsy: a local 
audit. Seizure 1993; 2: 287-290. 
8. Jay, G.W. and Leestma. J.E. Sudden death in epilepsy. Acra 
Neurologica Scor~dinavico 198 I ; 63 (Suppl 82): I-66. 
9. Johnson, R.H., Lambie. D.G. and Spa1ding.J.M.K. Neurocardi- 
ology. In: Neurogenic Abnomrolities of the Hew/. Major Pmb- 
lerns ht Neurology Vol 13 (Ed. J. Walton). London. Saunders. 
1984: pp. 59-1 I I. 
IO. Moss, G.. Staunton, C. and Stein, A.A. The centroneurogenic 
etiology of the acute respiratory distress syndrome: univer- 
sal species independent phenomenon. Anzerican Journal of 
Surgep 1973; 126: 137-141. 
I I. Schraeder. P.L. and Lathers, C.M. Paroxysmal autonomic dys- 
function, epileptogenic activity and sudden death. Epilepsy Re- 
search 1989; 3: 55-62. 
12. White. P., Grant. P., Mosier, J. and Craig, A. Changes in cere- 
bral dynamics associated with seizures. Neurology 1961; 11: 
354-36 I. 
lj. Oppenheimer. S.M. Cardiac dysfunction during seizures and 
the sudden death syndrome. Journal of r/w Royal Sociep of 
Medicine 1990: 83: 134-136. 
14. Blumhardt. L.. Smith, P and Owen. L. Electrocardiographic 
accompaniments of temporal lobe epileptic seizures. Lancer 
1986: 1: 1051-1055. 
15. Oppenheimer, S.M.. Cechetto. D.F. and Hachinski, V.C. Cere- 
brogenic cardiac arrhythmias cerebral electrocardiographic in- 
fluences and their role in sudden death. Archives of Neurology 
1990;47: 513-519. 
16. lani, C., Colicchio. G.. Attanasio, A., Mattia. D. and 
Manfredi, M. Cardiogenic syncope in temporal lobe epileptic 
seizures. Journal of Newologicnl and Neurosurgical Psychia- 
IT 1997: 63: 259-260. 
